1-9 of 9
tisagenlecleucel
Close
Sort by
Journal Articles

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Clinical Trials & Observations
Martina Pennisi, Miriam Sanchez-Escamilla, Jessica R. Flynn, Roni Shouval, Ana Alarcon Tomas, Mari Lynn Silverberg, Connie Batlevi, Renier J. Brentjens, Parastoo B. Dahi, Sean M. Devlin, Claudia Diamonte, Sergio Giralt, Elizabeth F. Halton, Tania Jain, Molly Maloy, Elena Mead, Maria Lia Palomba, Josel Ruiz, Bianca Santomasso, Craig S. Sauter, Michael Scordo, Gunjan L. Shah, Jae H. Park, Lucrecia Yanez San Segundo, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3397–3406.
https://doi.org/10.1182/bloodadvances.2020003885
Published: 2021
Includes: Supplemental data
Journal Articles

Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.

Journal: Blood Advances
Blood Adv (2021) 5 (4): 1136.
https://doi.org/10.1182/bloodadvances.2021004265
Published: 2021
Journal Articles

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Clinical Trials & Observations
Tania Jain, Andrea Knezevic, Martina Pennisi, Yunxin Chen, Josel D. Ruiz, Terence J. Purdon, Sean M. Devlin, Melody Smith, Gunjan L. Shah, Elizabeth Halton, Claudia Diamonte, Michael Scordo, Craig S. Sauter, Elena Mead, Bianca D. Santomasso, M. Lia Palomba, Connie W. Batlevi, Molly A. Maloy, Sergio Giralt, Eric Smith, Renier Brentjens, Jae H. Park, Miguel-Angel Perales, Sham Mailankody
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3776–3787.
https://doi.org/10.1182/bloodadvances.2020002509
Published: 2020
Includes: Supplemental data
Journal Articles

Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James E. Signorovitch, Vadim V. Romanov, Frederick L. Locke, David G. Maloney
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1432–1439.
https://doi.org/10.1182/bloodadvances.2019001304
Published: 2020
Includes: Supplemental data
Journal Articles

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Richard T. Maziarz, Stephen J. Schuster, Vadim V. Romanov, Elisha S. Rusch, Junlong Li, James E. Signorovitch, David G. Maloney, Frederick L. Locke
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1440–1447.
https://doi.org/10.1182/bloodadvances.2019001305
Published: 2020
Includes: Supplemental data
Journal Articles

Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management

Clinical Trials & Observations
Martina Pennisi, Tania Jain, Bianca D. Santomasso, Elena Mead, Kitsada Wudhikarn, Mari Lynne Silverberg, Yakup Batlevi, Roni Shouval, Sean M. Devlin, Connie Batlevi, Renier J. Brentjens, Parastoo B. Dahi, Claudia Diamonte, Sergio Giralt, Elizabeth F. Halton, Molly Maloy, Maria Lia Palomba, Miriam Sanchez-Escamilla, Craig S. Sauter, Michael Scordo, Gunjan Shah, Jae H. Park, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2020) 4 (4): 676–686.
https://doi.org/10.1182/bloodadvances.2019000952
Published: 2020
Journal Articles

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Richard T. Maziarz, Edmund K. Waller, Ulrich Jaeger, Isabelle Fleury, Joseph McGuirk, Harald Holte, Samantha Jaglowski, Stephen J. Schuster, Michael R. Bishop, Jason R. Westin, Stephan Mielke, Takanori Teshima, Veronika Bachanova, Stephen R. Foley, Peter Borchmann, Gilles A. Salles, Jie Zhang, Ranjan Tiwari, Lida B. Pacaud, Qiufei Ma, Constantine S. Tam
Journal: Blood Advances
Blood Adv (2020) 4 (4): 629–637.
https://doi.org/10.1182/bloodadvances.2019001026
Published: 2020
Includes: Supplemental data
Journal Articles

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

Clinical Trials & Observations
Rakesh Awasthi, Lida Pacaud, Edward Waldron, Constantine S. Tam, Ulrich Jäger, Peter Borchmann, Samantha Jaglowski, Stephen Ronan Foley, Koen van Besien, Nina D. Wagner-Johnston, Marie José Kersten, Stephen J. Schuster, Gilles Salles, Richard T. Maziarz, Özlem Anak, Christopher del Corral, Jufen Chu, Irina Gershgorin, Iulian Pruteanu-Malinici, Abhijit Chakraborty, Karen Thudium Mueller, Edmund K. Waller
Journal: Blood Advances
Blood Adv (2020) 4 (3): 560–572.
https://doi.org/10.1182/bloodadvances.2019000525
Published: 2020
Includes: Supplemental data
Journal Articles

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Clinical Trials & Observations
Michael R. Bishop, Richard T. Maziarz, Edmund K. Waller, Ulrich Jäger, Jason R. Westin, Joseph P. McGuirk, Isabelle Fleury, Harald Holte, Peter Borchmann, Christopher del Corral, Ranjan Tiwari, Özlem Anak, Rakesh Awasthi, Lida Pacaud, Vadim V. Romanov, Stephen J. Schuster
Journal: Blood Advances
Blood Adv (2019) 3 (14): 2230–2236.
https://doi.org/10.1182/bloodadvances.2019000151
Published: 2019